Geron Corporation Loses Chief Commercial Officer Following FDA Approval of RYTELO

1. Geron Corporation's Chief Commercial Officer, Anil Kapur, is leaving the company at the end of August 2024 to pursue new opportunities.
2. Kapur's departure comes shortly after Geron received FDA approval for its first drug, RYTELO (imetelstat), for treating adult patients with lower-risk myelodysplastic syndromes (MDS).
3. Andrew Grethlein, Executive Vice President and Chief Operating Officer, will take on the leadership of the commercial division on an interim basis.
4. Dawn Carter Bir, a member of Geron's Board of Directors, will assist Grethlein during the transitional period.
5. Geron is conducting a search for a permanent replacement for the Chief Commercial Officer position.